Roy Buchanan
Stock Analyst at JMP Securities
(4.99)
# 13
Out of 5,072 analysts
71
Total ratings
53.62%
Success rate
98.26%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $153 → $173 | $219.65 | -21.24% | 8 | Oct 3, 2025 | |
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $37.23 | +2.07% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $11.47 | +178.99% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $13.66 | +83.02% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.69 | +279.92% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.28 | +89.39% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.10 | +81.82% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.81 | +894.48% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $57.45 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $3.69 | +8.40% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $14 | $3.13 | +347.28% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $128.23 | -74.26% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.32 | +15.74% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $917.93 | -51.19% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $9.40 | +70.21% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.17 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153 → $173
Current: $219.65
Upside: -21.24%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $37.23
Upside: +2.07%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $11.47
Upside: +178.99%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $13.66
Upside: +83.02%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.69
Upside: +279.92%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.28
Upside: +89.39%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.10
Upside: +81.82%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.81
Upside: +894.48%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $57.45
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $3.69
Upside: +8.40%
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $3.13
Upside: +347.28%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $128.23
Upside: -74.26%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.32
Upside: +15.74%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $917.93
Upside: -51.19%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $9.40
Upside: +70.21%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.17
Upside: -